Copyright
©The Author(s) 2023.
World J Gastroenterol. Jun 28, 2023; 29(24): 3871-3882
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3871
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3871
Figure 3 Biomarker analysis.
A: Baseline: Progression-free survival (PFS) ≥ 19.7 vs PFS < 19.7; B: 1st Dose: PFS ≥ 19.7 vs PFS < 19.7; C: 2nd Dose: PFS ≥ 19.7 vs PFS < 19.7; D: 3rd Dose: PFS ≥ 19.7 vs PFS < 19.7; E: 4th Dose: PFS ≥ 19.7 vs PFS < 19.7; F: 5th Dose: PFS ≥ 19.7 vs PFS < 19.7; G: 6th Dose: PFS ≥ 19.7 vs PFS < 19.7. PFS: Progression-free survival.
- Citation: Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial. World J Gastroenterol 2023; 29(24): 3871-3882
- URL: https://www.wjgnet.com/1007-9327/full/v29/i24/3871.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i24.3871